Targeted protein degraders are an emerging modality. Their properties fall outside the traditional small-molecule property space and are in the ‘beyond rule of 5’ space. Consequently, drug discovery programs focused on developing orally bioavailable degraders are expected to face complex drug metabolism and pharmacokinetics (DMPK) challenges compared with traditional small molecules. Nevertheless, little information is available on the DMPK optimization of oral degraders. Therefore, in this review, we discuss our experience of these DMPK optimization challenges and present methodologies and strategies to overcome the hurdles dealing with this new small-molecule modality, specifically in developing oral degraders to treat cancer.
By Carina Cantrill, Prasoon Chaturved, Caroline Rynn, Jeannine, Petrig Schaffland, Isabelle Walter, Matthias B. Wittwer